To understand the future of these preclinical studies, we sat down with James Keck, Ph.D., who was recently recognized as a JAX President’s Innovation Fellow for his work creating mouse-based platforms to study the immune system, and evaluate new therapeutics for both safety and efficacy.
To improve glioma treatments, the tumors have to be attacked from every angle, and Roel Verhaak is working on multiple fronts to bring better care and outcomes to patients who now have nowhere to turn.
With genomic tumor testing, a negative result is not always definitive. In some cases a genomic variant can be present but not detected by the specific testing platform. Tests vary significantly and have different limitations, which impacts how results can and should be used for making treatment decisions.